TX-FLUENCE
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it will debut products at MJBizCon 2021, including its high-output SPYDR 2h, SPYDR Fang, waterproof RAZR Enclosed and next-generation RAPTR top light as well as its new lighting controls, Wireless Flex Dimming and the SHYFT Light Scheduler.
Following the announcement of its multiyear global research study results —which showcased the effects of broad-spectrum lighting solutions on crop yield and quality—Fluence will demo its innovative new products at the company’s MJBizCon booth, located at No. C3515.
“In our recently announced research results, Fluence noted a clear, positive impact on cannabis crop yield, cannabinoid content and overall plant quality under broad-spectrum lighting,” said David Cohen, CEO of Fluence. “According to the 2021 State of the Cannabis Lighting Market report , LED usage for cannabis cultivation has increased more than 45 percent for all stages of growth since the initial report in 2016. The efficacy of LED lighting solutions for cannabis cultivation is no longer a question. Cultivators have embraced the power of LEDs and are seeking new ways to harness broad-spectrum lighting technology to optimize their cultivation environments. Fluence’s innovative new products—informed by the latest photobiology research—will enable cultivators to achieve exceptional crop performance.”
The latest luminaires from Fluence include:
- SPYDR 2h: An extension of Fluence’s SPYDR series—featuring luminaires designed for single- or multitier growers who want to optimize grow space—the company’s high-output SPYDR 2h produces a photosynthetic photon flux of up to 2,080 μmol/s. Supported by results from Fluence’s multiyear global research studies observing cannabis growth under high light intensities, the SPYDR 2h is designed to maximize yields.
- SPYDR Fang: The SPYDR Fang is designed specifically for the retail buyer and built with Fluence’s trusted, research-backed and science-led engineering leveraged by commercial growers throughout the world.
- RAZR Enclosed: Following its debut in June 2021, the RAZR Modular System is now IP67 waterproof to withstand hyper-wet and humid environments within a vertical farm. The RAZR series is also now available with various spectral options, including broad-white as well as dual red and blue light. Fluence will showcase the system’s newest features through video at the company’s MJBizCon booth.
- RAPTR: Fluence’s latest top light solution serves as an advanced one-to-one high-pressure sodium replacement. The next-generation top light consumes 1,000 watts at a high output, plugging in seamlessly to a grower’s existing facility for streamlined retrofits.
“Fluence’s high-output SPYDR 2h will transform how cannabis cultivators approach each stage of plant production,” said Jordon Musser, chief product officer for Fluence. “We’ve seen incredible yield and quality metrics at high PPFDs and we’re excited to collaborate with our growers to incorporate high-intensity lighting and cultivation strategies into their operations.”
The company will also debut its innovative lighting controls, including:
- SHYFT: Available in North America, Fluence’s light scheduler, SHYFT, offers patented photoacclimation capability and daily photoperiod control for 0 to 10 V LED and dimmable fluorescent fixtures. At MJBizCon, visit the Fluence booth to see SHYFT control each of the company’s luminaires and witness its advanced lighting control capabilities.
- Wireless Flex Dimming: In addition to SHYFT, Fluence’s Wireless Flex Dimming solution leverages Bluetooth mesh technology to wirelessly control fixtures. With Wireless Flex Dimming’s plug-and-play design, growers gain increased flexibility over light levels with no wire installations or additional labor costs. Fluence team members will demo the product’s wireless capabilities from within the booth.
“MJBizCon is the world’s stage for unveiling leading cannabis innovations and we’re thrilled to debut multiple solutions that are advancing the global cannabis market forward,” said Lorrie Schultz, senior vice president of marketing for Fluence. “We’re eager to showcase our new products at MJBizCon and exemplify how Fluence is helping cannabis cultivators grow smarter.”
For more information on Fluence, its products and release dates for the company’s newest solutions, visit the team at MJBizCon from Oct. 20, 2021 to Oct. 22, 2021 at booth No. C3515 or explore Fluence’s website at www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005390/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom